Leukemia, Myelodysplasia, Transplantation
Conference Coverage
ADMIRAL results solidify gilteritinib as new standard for FLT3-mutated AML
AMSTERDAM – Patients treated with gilteritinib has superior overall survival, compared with four salvage chemotherapy regimens.
Conference Coverage
Guadecitabine offers limited advantage over other standards for high-risk AML
AMSTERDAM – In order to see this limited advantage with guadecitabine, patients had to undergo at least four cycles of treatment.
Conference Coverage
Rituximab and vemurafenib could challenge frontline chemotherapy for HCL
AMSTERDAM – The investigators called for randomized testing to compare the combination to standard chemotherapy in the frontline setting for hairy...
From the Journals
‘Robust antitumor immune responses’ observed in pediatric ALL
Tumor-associated CD8+ T cells responded to 86% of neoantigens tested and recognized 68% of neoepitopes tested in samples from pediatric ALL...
Conference Coverage
Risk model could help predict VTE in acute leukemia
AMSTERDAM – VTE risk modeling is available for patients with solid tumors, but a similar prognostic tool for leukemia patients has been missing....
Conference Coverage
AML variants before transplant signal need for aggressive therapy
AMSTERDAM – Patients who had genomic evidence of a lingering AML variant had worse posttransplant outcomes when they underwent reduced-intensity...
Latest News
For tough AML, half respond to selinexor plus chemotherapy
AMSTERDAM – The addition of selinexor looks promising in relapsed/refractory AML, but Karyopharm Therapeutics will be focusing first on approval...
From the Journals
Hedgehog signaling offers prognostic, therapeutic potential in CLL
Hedgehog signaling was associated with expression of GLI1, which could be a future therapeutic target.
Conference Coverage
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
Development plans for anti-CD19, anti-CD20 therapy include phase 2 studies in mantle cell, CD19 CAR T cell relapsers.
From the Journals
Novel chip system could improve preclinical drug studies
These chip systems could potentially reduce the use of animals and increase the efficiency of drug evaluations in preclinical studies.
Conference Coverage
Durable transfusion independence in MDS with imetelstat
AMSTERDAM – The telomerase inhibitor may also have disease-modifying properties, investigators suspect.